Christine A. White

IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma

David G. Maloney, Antonio J Grillo-López, Christine A. White et al. · Blood · 1997 · 1.7K citations

Medicine, Hematology, Oncology +14

Treatment With Ibritumomab Tiuxetan Radioimmunotherapy in Patients With Rituximab-Refractory Follicular Non-Hodgkin’s Lymphoma

Thomas E. Witzig, Ian W. Flinn, Leo I. Gordon et al. · Journal of Clinical Oncology · 2002 · 650 citations

Medicine, Hematology, Pharmacotherapy +14

Association of serum Rituximab (IDEC–C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin’s lymphoma

Neil L. Berinstein, A.J. Grillo-López, Christine A. White et al. · Annals of Oncology · 1998 · 523 citations · Full text

Medicine, Hematology, Oncology +15

Safety of Yttrium-90 Ibritumomab Tiuxetan Radioimmunotherapy for Relapsed Low-Grade, Follicular, or Transformed Non-Hodgkin’s Lymphoma

Thomas E. Witzig, Christine A. White, Leo I. Gordon et al. · Journal of Clinical Oncology · 2003 · 291 citations

Pharmacy, Oncology, Pharmacotherapy +17

Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial

Gregory A. Wiseman, Leo I. Gordon, Pratik S. Multani et al. · Blood · 2002 · 266 citations · Full text

Medicine, Immunology, Oncology +14